Quay Pharma has expanded its range of services following Medicines and Healthcare products Regulatory Agency (MHRA) approval for the manufacture of commercial batches of drugs at its two production sites in Deeside and Bromborough
This extension to its manufacturing capabilities will allow Quay to manufacture commercial batches and support orphan drug companies for whom continuity of manufacturing for small quantities of product is desirable, according to the company.
Quay’s manufacturing areas are compliant with Good Manufacturing Practice (GMP) and the company also holds a licence for the manufacture and testing of Investigational Medicinal Products (IMPs), including medical devices.
The company said that it is one of the few companies licenced by the MHRA to carry out Specials Manufacture – the production of unlicensed medical products developed to meet the particular clinical requirements of individual patients whose needs cannot be met by licensed medicines.
Maireadh Pedersen, CEO of Quay, said: “The attainment of our Commercial Licence, in combination with our Specials Licence, is another important step in Quay’s growth and development and demonstrates our on-going commitment to support our key customers who develop drugs for rare and neglected diseases.
“We now have the added flexibility to be able to help our clients take their drugs from successful trial to initial commercial manufacture in one seamless process.”